362525-67-5

Upstream product

• 754230-78-9 3-(benzyloxy)-5-bromopyridine-2-amine 
• 814-75-5 3-bromo-butanone 
• 362525-66-4 6,8-Dibromo-2,3-dimethylimidazo[1,2-a]pyridine 
• 100-51-6 benzyl alcohol 
• 20194-18-7 sodium phenyl-methanolate 

Downstream Products

• 362525-68-6 8-benzyloxy-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase

A series of novel 8-indanylamino- and 8-indanyloxy-substituted imidazo[1,2-a]pyridines with reduced lipophilicity was synthesized from easily accessible starting compounds. The anti-secretory activity of these compounds has been assessed in a competitive

Synthesis and evaluation of 7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a] pyridines as potassium-competitive acid blockers

7H-8,9-Dihydropyrano[2,3-c]imidazo[1,2-a]pyridines with excellent physicochemical and pharmacological properties were identified that represent interesting candidates for further development as potassium-competitive acid blockers (P-CABs). The title compounds were prepared following synthetic pathways that relied either on a Claisen rearrangement/cross-metathesis reaction or on the (asymmetric) reduction of prochiral ketones. The influence of the character of the substituents R3, R6, and Ar on the biological activity and the physicochemical properties of the target compounds was examined. In contrast to the parent system (R6 = H), compounds in which R6 represents a carboxamide residue generally show improved in vivo activity and favorable pKa/log D values. Whereas variation of R3 is useful to obtain target compounds with modified basicity and lipophilicity, strong inhibition of the H+/K+-ATPase and potent in vivo activity is observed for R3 = methyl only. Small modifications of the aryl group, e.g., replacement of hydrogen versus a fluoro atom or a methyl group, are allowed. The (9S)-enantiomers are responsible for the gastric acid secretion inhibiting action, whereas the (9R)-enantiomers are virtually inactive.

POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS

The invention relates to imidazopyridines of a certain formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion-inhibiting properties.

Alkylated imidazopyridine derivatives

Compounds of the formula 1 in which the substituents have the meanings mentioned in the description are suitable for the prevention and treatment of gastrointestinal diseases.

Prodrugs of imidazopyridine derivatives

Compounds of formula (1), in which the substituents have the meanings mentioned in the description are suitable for the prevention and treatment of gastrointestinal diseases.

Imidazopyridin-8-ones

Compounds of the formula (1), in which the substituents have the meanings mentioned in the description, are valuable intermediates for preparing active compounds for the prevention and treatment of gastrointestinal diseases.

NITROSATED IMIDAZOPYRIDINES

The invention relates to nitrosated imidazopyridines of a certain formula (I), in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion-inhibiting, anti-inflammatory and antibacterial properties.